Pharmacovigilance Working Party

There is an active Pharmacovigilance Working Party (PhVWP) which meets every month, with the Chairman reporting to the plenary meeting of the CPMP. PhVWP has already adopted a number of guidelines. Of particular interest are the following two ... 

The common forum is the Pharmacovigilance Working Party of the Committee for Human Medicinal Products (CHMP)... 

Dr. June Raim, Director of the Vigilance and Risk Management of Medicines Division, Medicines and Healthcare Products Regulatory Agency, London, UK and Chair of the EU Pharmacovigilance Working Party... 

The CPMP working parties are concerned with biotechnology, efficacy, safety, and pharmacovigilance. The CVMP working parties are concerned with safety of residues, immunological veterinary products, veterinary pharmacovigilance, and efficacy. 

The Committee for Human Medicinal Products (CHMP), Committee for Veterinary Medicinal Products (CVMP) and Committee for Orphan Medicinal Products (COMP) are the major committees run by this agency to ensure the above objectives. Additional support comes from more than 90 Working Parties (e.g., on efficacy, safety, quality, biotechnology, pharmacovigilance, blood and plasma, etc.) as well as ad-hoc Expert Groups (on subjects like pediatric use, bioterrorism, oncology, anti-HIV drugs, etc.) and also approximately 2500 European experts from competent national authorities. 

---